Table 1 Clinicopathologic features of... | American Society of Hematology

Table 1

Clinicopathologic features of the patients with gastric DLBCL (MALT)

Patient no.	Sex	Age, y	Depth of tumor invasion*	Tumor response to HP eradication	Current status	Histology†	t(11;18)‡
1	F	48	Muscularis propria	CR		DLBCL-P	−
2	M	21	Muscularis propria	PD	Chemotherapy	DLBCL-P	−
3	F	63		SD	Chemotherapy	MALToma-P	+
4	F	68		CR		MALToma-P	−
5	F	52	Submucosa	PD	Chemotherapy	MALToma-P	−
6	F	42	Serosa	CR		MALToma-P	−
7	F	66	Serosa	CR		DLBCL-P	−
8	F	71	Muscularis propria	CR		MALToma-P	−
9	F	54		CR		MALToma-P	−
10	M	83	Muscularis propria	PD	Chemotherapy	MALToma-P	−
11	F	52	Submucosa	CR		MALToma-P	−
12	F	73	Muscularis propria	CR		DLBCL-P	−
13	M	46	Submucosa	CR		DLBCL-P	−
14	F	38		CR		MALToma-P	−
15	M	73	Serosa	PD	Chemotherapy	DLBCL-P	−
16	F	45	Muscularis propria	PD	Chemotherapy	MALToma-P	−
17	F	56	Submucosa	CR		MALToma-P	−
18	F	59	Serosa	PD	Chemotherapy + gastrectomy	DLBCL-P	−
19	F	65		CR		DLBCL-P	−
20	M	35	Submucosa	CR		DLBCL-P	−
21	F	73		CR		MALToma-P	−
22	M	45	Serosa	SD	Chemotherapy	DLBCL-P	−
23	F	53	Submucosa	SD	Chemotherapy	DLBCL-P	−
24	F	80	Muscularis propria	PD	Chemotherapy	MALToma-P	−
25	M	70	Submucosa	CR		DLBCL-P	−
26	F	84	Submucosa	CR		DLBCL-P	−

Patient no.	Sex	Age, y	Depth of tumor invasion*	Tumor response to HP eradication	Current status	Histology†	t(11;18)‡
1	F	48	Muscularis propria	CR		DLBCL-P	−
2	M	21	Muscularis propria	PD	Chemotherapy	DLBCL-P	−
3	F	63		SD	Chemotherapy	MALToma-P	+
4	F	68		CR		MALToma-P	−
5	F	52	Submucosa	PD	Chemotherapy	MALToma-P	−
6	F	42	Serosa	CR		MALToma-P	−
7	F	66	Serosa	CR		DLBCL-P	−
8	F	71	Muscularis propria	CR		MALToma-P	−
9	F	54		CR		MALToma-P	−
10	M	83	Muscularis propria	PD	Chemotherapy	MALToma-P	−
11	F	52	Submucosa	CR		MALToma-P	−
12	F	73	Muscularis propria	CR		DLBCL-P	−
13	M	46	Submucosa	CR		DLBCL-P	−
14	F	38		CR		MALToma-P	−
15	M	73	Serosa	PD	Chemotherapy	DLBCL-P	−
16	F	45	Muscularis propria	PD	Chemotherapy	MALToma-P	−
17	F	56	Submucosa	CR		MALToma-P	−
18	F	59	Serosa	PD	Chemotherapy + gastrectomy	DLBCL-P	−
19	F	65		CR		DLBCL-P	−
20	M	35	Submucosa	CR		DLBCL-P	−
21	F	73		CR		MALToma-P	−
22	M	45	Serosa	SD	Chemotherapy	DLBCL-P	−
23	F	53	Submucosa	SD	Chemotherapy	DLBCL-P	−
24	F	80	Muscularis propria	PD	Chemotherapy	MALToma-P	−
25	M	70	Submucosa	CR		DLBCL-P	−
26	F	84	Submucosa	CR		DLBCL-P	−

HP indicates H pylori; CR, complete remission; PD, progressive disease; SD, stable disease; +, positive; and −, negative.

Evaluated by endoscopic ultrasonography (20 cases) and histologic examination of surgical specimens (1 case).

Histology: DLBCL predominant (DLBCL-P), MALT lymphoma predominant (MALToma-P).

t(11;18) was identified by a multiplex RT-PCR of the API2-MALT1 chimeric transcript or by FISH.